M. Jäger, A. Schoberth, P. Ruf, J. Hess, M. Hennig et al., Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3), Cancer Research, vol.72, issue.1, pp.24-32, 2012.
DOI : 10.1158/0008-5472.CAN-11-2235

M. Sebastian, Review of CatmAb in the treatment of malignant ascites, Cancer Manag Res, vol.2, pp.283-289, 2010.

P. Went, A. Lugli, S. Meier, M. Bundi, M. Mirlacher et al., Frequent EpCam protein expression in human carcinomas, Human Pathology, vol.35, issue.1, pp.122-130, 2004.
DOI : 10.1016/j.humpath.2003.08.026

G. Spizzo, D. Fong, M. Wurm, C. Ensinger, P. Obrist et al., EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis, Journal of Clinical Pathology, vol.64, issue.5, pp.415-435, 2011.
DOI : 10.1136/jcp.2011.090274

M. Schmitt, A. Schmitt, P. Reinhardt, B. Thess, B. Manfras et al., Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes, Int J Oncol, vol.25, pp.841-849, 2004.

R. Zeidler, G. Reisbach, B. Wollenberg, S. Lang, S. Chaubal et al., Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing, J Immunol, vol.163, pp.1246-52, 1999.

R. Zeidler, J. Mysliwietz, M. Csánady, A. Walz, I. Ziegler et al., The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells, Br J Cancer, vol.83, pp.261-267, 2000.

M. Schmidt, D. Hasenclever, M. Schaeffer, D. Boehm, C. Cotarelo et al., Prognostic Effect of Epithelial Cell Adhesion Molecule Overexpression in Untreated Node-Negative Breast Cancer, Clinical Cancer Research, vol.14, issue.18, pp.5849-55, 2008.
DOI : 10.1158/1078-0432.CCR-08-0669

G. Gastl, G. Spizzo, P. Obrist, M. Dünser, and G. Mikuz, Ep-CAM overexpression in breast cancer as a predictor of survival, The Lancet, vol.356, issue.9246, pp.1981-1983, 2000.
DOI : 10.1016/S0140-6736(00)03312-2

F. Hirschhaeuser, S. Walenta, and W. Mueller-klieser, Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action, Cancer Immunology, Immunotherapy, vol.27, issue.6, pp.1675-84, 2010.
DOI : 10.1007/s00262-010-0894-1

M. Heiss, M. Ströhlein, M. Jäger, R. Kimmig, A. Burges et al., Immunotherapy of malignant ascites with trifunctional antibodies, International Journal of Cancer, vol.1, issue.3, pp.435-478, 2005.
DOI : 10.1002/ijc.21165

A. Burges, P. Wimberger, C. Kümper, V. Gorbounova, H. Sommer et al., Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM x Anti-CD3 Antibody: A Phase I/II Study, Clinical Cancer Research, vol.13, issue.13, pp.3899-905, 2007.
DOI : 10.1158/1078-0432.CCR-06-2769

M. Heiss, P. Murawa, P. Koralewski, E. Kutarska, O. Kolesnik et al., The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial, International Journal of Cancer, vol.84, issue.Suppl, pp.2209-2230, 2010.
DOI : 10.1002/ijc.25423

M. Miyara, Y. Yoshioka, A. Kitoh, T. Shima, K. Wing et al., Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor, Immunity, vol.30, issue.6, pp.899-911, 2009.
DOI : 10.1016/j.immuni.2009.03.019

L. Zitvogel, O. Kepp, and G. Kroemer, Decoding Cell Death Signals in Inflammation and Immunity, Cell, vol.140, issue.6, pp.798-804, 2010.
DOI : 10.1016/j.cell.2010.02.015

M. Obeid, A. Tesniere, F. Ghiringhelli, G. Fimia, L. Apetoh et al., Calreticulin exposure dictates the immunogenicity of cancer cell death, Nature Medicine, vol.279, issue.1, pp.54-61, 2007.
DOI : 10.1038/nm1523
URL : https://hal.archives-ouvertes.fr/inserm-00451702

L. Apetoh, F. Ghiringhelli, A. Tesniere, M. Obeid, C. Ortiz et al., Toll-like receptor 4???dependent contribution of the immune system to anticancer chemotherapy and radiotherapy, Nature Medicine, vol.289, issue.9
DOI : 10.1038/nm1622
URL : https://hal.archives-ouvertes.fr/hal-00316924

M. Michaud, I. Martins, A. Sukkurwala, S. Adjemian, Y. Ma et al., Autophagydependent anticancer immune responses induced by chemotherapeutic agents in mice

L. Zitvogel and G. Kroemer, Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects, Journal of Clinical Investigation, vol.119, pp.2127-2157, 2009.
DOI : 10.1172/JCI39991

L. Zitvogel, O. Kepp, and G. Kroemer, Immune parameters affecting the efficacy of chemotherapeutic regimens, Nature Reviews Clinical Oncology, vol.23, issue.3, pp.151-60, 2011.
DOI : 10.1038/nrclinonc.2010.223

J. Casazza, M. Betts, D. Price, M. Precopio, L. Ruff et al., T lymphocytes with cellular maturation, The Journal of Experimental Medicine, vol.151, issue.13, pp.2865-77, 200625.
DOI : 10.1016/S0145-305X(02)00039-3

M. Schmueck, A. Fischer, B. Hammoud, G. Brestrich, H. Fuehrer et al., Preferential Expansion of Human Virus-Specific Multifunctional Central Memory T Cells by Partial Targeting of the IL-2 Receptor Signaling Pathway: The Key Role of CD4+ T Cells, The Journal of Immunology, vol.188, issue.10, pp.155189-98
DOI : 10.4049/jimmunol.1103763

E. Nemes, E. Lugli, L. Bertoncelli, M. Nasi, M. Pinti et al., CD4+ T-cell differentiation, regulatory T cells and gag-specific T lymphocytes are unaffected by CD4-guided treatment interruption and therapy resumption, AIDS, vol.25, issue.12, pp.1443-53, 2011.
DOI : 10.1097/QAD.0b013e328347b5e2

N. Marshall and S. Swain, Cytotoxic CD4 T Cells in Antiviral Immunity, Journal of Biomedicine and Biotechnology, vol.187, issue.7, pp.954602-954612, 2011.
DOI : 10.1182/blood-2008-06-162727

H. Woopen, K. Pietzner, S. Darb-esfahani, G. Oskay-oezcelik, and J. Sehouli, Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature, Medical Oncology, vol.32, issue.5
DOI : 10.1007/s12032-012-0285-x

M. Ströhlein, R. Siegel, M. Jäger, H. Lindhofer, K. Jauch et al., Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis, Journal of Experimental & Clinical Cancer Research, vol.28, issue.1, p.18, 2009.
DOI : 10.1186/1756-9966-28-18

M. Ott, F. Marmé, G. Moldenhauer, H. Lindhofer, M. Hennig et al., Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites, International Journal of Cancer, vol.2, issue.9, pp.2195-203, 2012.
DOI : 10.1002/ijc.26258

A. Regnault, D. Lankar, V. Lacabanne, A. Rodriguez, C. Théry et al., Fc?? Receptor???mediated Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class I???restricted Antigen Presentation after Immune Complex Internalization, The Journal of Experimental Medicine, vol.70, issue.2, pp.371-80, 199918.
DOI : 10.1084/jem.184.3.863

F. Pagès, A. Berger, M. Camus, F. Sanchez-cabo, A. Costes et al., Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer, New England Journal of Medicine, vol.353, issue.25, pp.2654-66, 2005.
DOI : 10.1056/NEJMoa051424

J. Mumm, J. Emmerich, X. Zhang, I. Chan, L. Wu et al., IL-10 Elicits IFN??-Dependent Tumor Immune Surveillance, Cancer Cell, vol.20, issue.6, pp.781-96, 2011.
DOI : 10.1016/j.ccr.2011.11.003

J. Emmerich, J. Mumm, I. Chan, D. Laface, H. Truong et al., IL-10 Directly Activates and Expands Tumor-Resident CD8+ T Cells without De Novo Infiltration from Secondary Lymphoid Organs, Cancer Research, vol.72, issue.14, pp.3570-81, 2012.
DOI : 10.1158/0008-5472.CAN-12-0721

M. Chao, S. Jaiswal, R. Weissman-tsukamoto, A. Alizadeh, A. Gentles et al., Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47, Science Translational Medicine, vol.2, issue.63, pp.63-94, 2010.
DOI : 10.1126/scitranslmed.3001375

T. Panaretakis, O. Kepp, U. Brockmeier, A. Tesniere, A. Bjorklund et al., Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death, The EMBO Journal, vol.65, issue.5, pp.578-90, 2009.
DOI : 10.1074/jbc.M512073200

S. Hoves, V. Sutton, N. Haynes, E. Hawkins, F. Ruiz et al., A Critical Role for Granzymes in Antigen Cross-Presentation through Regulating Phagocytosis of Killed Tumor Cells, The Journal of Immunology, vol.187, issue.3, pp.1166-75, 2011.
DOI : 10.4049/jimmunol.1001670

S. Ahrens, S. Zelenay, D. Sancho, P. Han?, S. Kjaer et al., F-Actin Is an Evolutionarily Conserved Damage-Associated Molecular Pattern Recognized by DNGR-1, a Receptor for Dead Cells, Immunity, vol.36, issue.4, pp.635-680, 2012.
DOI : 10.1016/j.immuni.2012.03.008

I. Martins, A. Tesniere, O. Kepp, M. Michaud, F. Schlemmer et al., Chemotherapy induces ATP release from tumor cells, Cell Cycle, vol.8, issue.22, pp.3723-3731, 2009.
DOI : 10.4161/cc.8.22.10026

F. Ghiringhelli, L. Apetoh, A. Tesniere, L. Aymeric, Y. Ma et al., Activation of the NLRP3 inflammasome in dendritic cells induces IL-1?????dependent adaptive immunity against tumors, Nature Medicine, vol.7, issue.10, pp.1170-1178, 2009.
DOI : 10.1038/nm.2028
URL : https://hal.archives-ouvertes.fr/hal-00419823

F. Chalmin, G. Mignot, M. Bruchard, A. Chevriaux, F. Végran et al., Stat3 and Gfi-1 Transcription Factors Control Th17 Cell Immunosuppressive Activity via the Regulation of Ectonucleotidase Expression, Immunity, vol.36, issue.3, pp.362-73, 2012.
DOI : 10.1016/j.immuni.2011.12.019
URL : https://hal.archives-ouvertes.fr/inserm-00821485

J. Stagg, P. Beavis, U. Divisekera, M. Liu, A. Möller et al., CD73-Deficient Mice Are Resistant to Carcinogenesis, Cancer Research, vol.72, issue.9, pp.2190-2196, 2012.
DOI : 10.1158/0008-5472.CAN-12-0420